Retatrutide RetaSlim (PeptoLabs) 20/40 mg Pen

How Retatrutide works

• Affects appetite regulation mechanisms

• Supports control of dietary calorie intake

• Participates in metabolic processes

• Is being studied in the field of fat mass reduction

• Affects hormonal hunger signals

Benefits of Retatrutide RetaSlim

• Modern triple agonist of GLP-1 / GIP / GCGR

• Innovative approach to weight control

• Convenient injection pen format

• Precise dosage of 40 mg/3 ml

• Actively studied in the field of metabolism

Who may be interested in Retatrutide

The product attracts the attention of people interested in:

• Modern peptides for weight control

• Metabolic research

• Appetite regulation

• Biohacking

• Innovative anti-age approaches

Pharmacodynamics of the Retatrutide RetaSlim PeptoLabs 40 mg pen

The product is a ready-to-use injectable solution containing 40 mg of the active substance. It is supplied in a convenient pen, making it easy to use anywhere.

Retatrutide 20/40 mg pen is designed to treat obesity, type 2 diabetes and possibly other metabolic disorders.

It is a multi-target incretin receptor agonist, meaning that it activates three types of receptors at once:

• GLP-1 (glucagon-like peptide-1) reduces appetite, slows gastric emptying and improves insulin sensitivity.

• GIP (glucose-dependent insulinotropic peptide) regulates insulin secretion and fat metabolism.

• Glucagon receptors participate in the regulation of energy metabolism and help burn fat.

The product mimics the effects of natural gastrointestinal hormones that regulate hunger and satiety, blood glucose levels and the rate of fat burning.

Clinical trials have shown very high efficacy in reducing body weight, up to 24% of initial weight over 48 weeks in people with obesity.

Like other GLP-1 agonists, Retatrutide may cause some side effects, including nausea, vomiting, diarrhoea, constipation and reduced appetite.

Retatrutide may be contraindicated in cases of severe gastrointestinal disease, cancer risks (especially a history of thyroid tumours), pregnancy and breastfeeding, pancreatitis (past or current), and severe liver or kidney dysfunction.

The product mimics the effects of natural gastrointestinal hormones that regulate hunger and satiety, blood glucose levels and the rate of fat burning.

Clinical trials have shown very high efficacy in reducing body weight, up to 24% of initial weight over 48 weeks in people with obesity.

Like other GLP-1 agonists, Retatrutide may cause some side effects, including nausea, vomiting, diarrhoea, constipation and reduced appetite.

Retatrutide may be contraindicated in cases of severe gastrointestinal disease, cancer risks (especially a history of thyroid tumours), pregnancy and breastfeeding, pancreatitis (past or current), and severe liver or kidney dysfunction. (Retatrutide)  RetaSlim.

Use:

Consult a doctor before use. On average, a weight-loss course lasts 36 to 48 weeks. Injections are administered subcutaneously once a week in the upper arm, thigh or abdomen. Treatment should begin with the lowest dosages, which are then increased gradually only if well tolerated, approximately as follows:

• Weeks 1-4, 2 mg each;

• Weeks 5-8, 4 mg each;

• Weeks 9-12, 6 mg each;

• From week 13, 8-12 mg each.

Exceeding the maximum dosage is not recommended.

Pen dosage calculation in clicks for 20 mg:

• 1 click = 66.7 mcg

• 15 clicks = 1 mg

• 38 clicks = 2.5 mg

• 45 clicks = 3 mg

• 60 clicks = 4 mg

Pen dosage calculation in clicks for 40 mg:

• 1 click = 0.133 mg

• 19 clicks = 2.5 mg

• 23 clicks = 3 mg

• 38 clicks = 5 mg

The product is intended for research purposes only.  The information was collected through numerous studies and analyses conducted over many years and is not intended to diagnose, treat or prevent any disease.

*All results are individual and depend on your state of health